Alnylam Pharmaceuticals Inc (ALNY) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate Alnylam’s ability to scale its RNAi portfolio, boosting revenue and validating its pipeline, which could reshape treatment landscapes for rare and common diseases.

Key Takeaways

• ONPATTRO revenue $102M, 13% QoQ growth
• Vutrisiran Phase 3 results positive, NDA filed
• OXLUMO $9M revenue, strong initial uptake
• Total product sales $135.8M, 89% YoY increase
• Pipeline targeting common diseases: hypertension, NASH, gout

Pulse Analysis

Alnylam continues to solidify its leadership in the RNA interference (RNAi) therapeutics space, a market projected to exceed $10 billion by 2028. The company’s Q1 2021 earnings underscore a robust commercial engine, with ONPATTRO delivering $102 million in net revenue and a 13% sequential increase despite lingering pandemic pressures. Complementary launches such as OXLUMO and sustained GIVLAARI sales broaden the revenue base, while high gross margins reflect the premium pricing power of disease‑modifying RNAi drugs. This financial momentum positions Alnylam to fund its expanding pipeline and pursue strategic acquisitions.

The pipeline narrative is equally compelling. Positive Phase 3 data for vutrisiran, an RNAi therapy for hereditary transthyretin amyloidosis, led to an FDA NDA filing, promising a near‑term addition to the approved TTR franchise. Parallel advances in lumasiran for primary hyperoxaluria type 1 and collaborations on inclisiran (Leqvio) and fitusiran broaden therapeutic reach across rare and prevalent indications. Notably, Alnylam is leveraging its RNAi platform to enter common disease arenas—ALN‑AGT for hypertension, ALN‑HSD for NASH, and CNS programs with Regeneron—signaling a strategic shift from niche markets to larger patient populations.

Strategically, Alnylam’s five‑year P5x25 roadmap targets a >40% compound annual revenue growth rate and sustainable non‑GAAP profitability by 2025. The company’s expanding global market access, with ONPATTRO now available in over 30 countries, underpins this ambition. Investors are likely to view the combination of accelerating commercial traction, a deepening pipeline, and clear long‑term growth targets as a catalyst for valuation uplift, especially as RNAi therapies gain broader acceptance across the pharmaceutical landscape.